Skip to main content
. Author manuscript; available in PMC: 2022 Jul 7.
Published in final edited form as: J Thorac Oncol. 2021 Apr 8;16(7):1149–1165. doi: 10.1016/j.jtho.2021.03.013

Figure 2. Histopathological characterization of the LUAD-0061AS3 PDX and sensitivity to ERBB therapy.

Figure 2.

Figure 2.

A. H&E stained samples demonstrated a typical appearance of mucinous adenocarcinoma cells with abundant eosinophilic cytoplasm and eccentric nuclei forming gland-like structures filled with mucin. IHC staining of TTF1 was performed to compare with the original patient sample. B. Cytopathological characterization was performed for an attached cell culture of LUAD-0061AS3cl (unstained, phase-contrast microscopy) and stained cell suspension (Liu stain). C. SLC3A2-NRG1 fusion-specific PCR was performed from cDNA isolated from PDX tissue (left) and cell line (right). cDNA from HBEC-DNP53 was used as a negative control to exclude non-specific amplification. NC: negative control. D-E. LUAD-0061AS3 (D) and MDA-MB-175-VII (E) cells were treated with afatinib (0.05 μM) or GSK2849330 (0.1 μM and 1 μM) and counted at 48 h intervals to establish growth curves. Results represent the mean ± SD of two independent measurements.